Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC Keeping it real board for pro and con discussions -- Ignore unavailable to you. Want to Upgrade?

To: drkaz who wrote (204)	5/16/2015 9:16:23 AM
From: Rawnoc	1 Recommendation Recommended By NewMoney_812 Respond to of 326

Remember ZincFinger having a temper tantrum over this? Turns out my sources were 100% correct. I called it back in January. Now how could I have known this? Thursday, January 29, 2015 1:03:49 PM Re: nanopatent post# 107549 Post # of 111556 THIS JUST IN FROM MY SOURCES: Management is not optimistic about Ebolacide2 because the shape of the virus is not as defined and symmetrical as other viruses, so the attachment points may not be as effective. Say good night to Ebolacide2. 2015 is dead.

To: drkaz who wrote (204)	5/16/2015 9:16:54 AM
From: Rawnoc	1 Recommendation Recommended By NewMoney_812 Respond to of 326

One of my sources specifically said Seymour was concerned about Ebolacide 2 attachment points due to the shape of the virus. This was immediately attacked and dismissed as ridiculous and ignorant of how the 'cides work. Well look what NNVC just said in the 10Q: "It is also likely that the NPC1-binding site on Ebolavirus glycoprotein, which is thought to be buried, may have been substantially inaccessible to our drug candidates." My sources remain 100% accurate.